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RESEARCH ARTICLE
The significance of anti-neuronal 
antibodies for acute psychiatric disorders: 
a retrospective case–controlled study
Morten B. Schou1,2*†, Sverre Georg Sæther1,3†, Ole Kristian Drange1,2, Karoline Krane‑Gartiser1,2, 
Solveig K. Reitan1,4, Arne E. Vaaler1,2 and Daniel Kondziella1,5
Abstract 
Background: The clinical significance of anti‑neuronal antibodies in patients with psychiatric disorders, but without 
encephalitis, remains unknown. In patients admitted to acute psychiatric inpatient care we aimed to identify clinical 
features distinguishing anti‑neuronal antibody positive patients from matched controls.
Results: Patients who were serum‑positive to N‑methyl d‑aspartate receptor (NMDAR) (n = 21), contactin‑associated 
protein 2 (CASPR2) (n = 14) and/or glutamic acid decarboxylase 65 (GAD65) (n = 9) antibodies (cases) were age and 
sex matched (1:2) with serum‑negative patients from the same cohort (controls). The prevalence and severity of 
psychiatric symptoms frequently encountered in NMDAR, CASPR2 and GAD65 antibody associated disorders were 
compared in cases and controls. NMDAR, CASPR2 and GAD65 antibody positive patients did not differ in their clinical 
presentation from matched serum negative controls.
Conclusion: In this cohort, patients with and without NMDAR, CASPR2 and GAD65 antibodies admitted to acute 
psychiatric inpatient care had similar psychiatric phenotypes. This does not exclude their clinical relevance in sub‑
groups of patients, and studies further investigating the clinical significance of anti‑neuronal antibodies in patients 
with psychiatric symptomatology are needed.
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Background
Anti-neuronal antibodies are associated with autoim-
mune encephalitis, which often presents with psychiatric 
symptoms [1]. We recently found serum anti-neuronal 
antibodies [Immunoglobulin (Ig) G, IgA and/or IgM] in 
12% of 925 patients consecutively admitted to acute psy-
chiatric inpatient care [N-methyl d-aspartate receptor 
(NMDAR) antibodies in 7.6%, contactin-associated pro-
tein 2 (CASPR2) antibodies in 2.5%, and glutamic acid 
decarboxylase 65 (GAD65) antibodies in 1.9%] [2]. The 
IgG isotype of NMDAR, CASPR2 and GAD65 antibodies 
has been associated with autoimmune encephalitis with 
prominent psychiatric features [1]. The IgA and IgM iso-
types of NMDAR antibodies have been associated with 
psychotic symptoms in dementia [3, 4], and there is some 
evidence that they have pathogenic potential [5]. In a 
recent meta-analysis, Grain et al. found that GAD65 anti-
bodies are more prevalent in patients with psychotic dis-
orders compared to controls [6]. The role of any of these 
antibodies in psychiatric patients without evidence of 
autoimmune encephalitis is, however, not clear. This is an 
important issue to address because these patients might 
benefit from immunotherapy [7].
The prevalence of anti-neuronal antibodies in patients 
with psychiatric disorders has been investigated in sev-
eral studies [2, 8–10]. However, it might be that the 
traditional psychiatric diagnostic classifications [e.g. 
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International Classification of Diseases-10 (ICD-10)] are 
inadequate for the plethora of autoimmune psychiatric 
symptoms [11, 12]. Consequently, we chose a different 
approach. In this large single-center study, we searched 
for differences in the clinical phenotypes of patients 
admitted to acute psychiatric inpatient care who tested 
either positive or negative for three well-known anti-neu-
ronal antibodies (NMDAR, CASPR2 and GAD65). We 
hypothesized that psychiatric patients testing positive 
to a specific antibody (e.g. anti-NMDAR) would have an 
increased frequency and/or severity of psychiatric symp-
toms typically seen in neurological syndromes associated 
with that antibody (e.g. anti-NMDAR encephalitis).
Methods
Setting
This case-controlled study was performed in an acute 
psychiatric inpatient clinic in a university center (St. 
Olavs Hospital, Trondheim University Hospital, Trond-
heim, Norway). The hospital receives all patients 
(≥ 18 years) admitted to acute psychiatric inpatient care 
in the catchment area. The most common reasons for 
referral include major depression, bipolar disorder, schiz-
ophrenia spectrum disorders, personality disorders, anxi-
ety disorders or substance induced psychiatric disorders. 
The only inclusion criterion was admission to acute psy-
chiatric inpatient care. Exclusion criteria were inability to 
give informed consent, discharge before consent could be 
obtained, or lack of proficiency in Norwegian or English.
Patients
A total of 654 consecutive patients were admitted during 
7 months in 2011–2012. Three hundred and forty patients 
(52%) consented to participate in the study, of which 41 
tested positive for NMDAR, CASPR2 and/or GAD65 anti-
bodies (IgA, IgG or IgM). None tested positive for antibodies 
directed to Leucine-rich glioma-inactivated protein 1 (LGI1), 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic  acid 
receptor (AMPAR) or γ-aminobutyric acid B receptor 
 (GABABR) [2]. Eighty-two anti-neuronal antibody nega-
tive controls were chosen from the same cohort (i.e. 2 con-
trols for each case) (Fig. 1). Controls were selected randomly 
among patients with the same sex and age (± 5 years) as each 
case. If no such patient was present in the cohort, the age 
interval was increased (± 10 years, ± 15 years).
Variables
Variables of symptomatology were selected following a 
systematic literature search for psychiatric symptoma-
tology in disorders associated with NMDAR, CASPR2 
and GAD65 antibodies. Comparisons were made only 
for symptoms associated with each specific anti-neu-
ronal antibody. See Additional file  1 for search strategy 
and citations on the papers reviewed. Symptom variables 
were included only if they either were available from the 
data collected during the inclusion period (2011–2012) 
or could be reliably assessed during retrospective chart 
review. Symptom variables included were; hallucinations, 
delusions, lowered mood, elevated mood, irritability, dis-
inhibition, agitation, disorientation, symptom fluctua-
tion, and sleep problems. The symptom variables anxiety, 
catatonia and apathy were also extracted in the literature 
review but were deemed too unreliable to be assessed by 
retrospective chart review. A subset of symptom vari-
ables was associated with exclusively one or two of the 
antibodies assessed in this study (Table 1). 
On the first day following admission, the attending 
physicians evaluated the degree of agitation with the 
Positive and Negative Syndrome Scale-Excited Com-
ponent (PANSS-EC) [13], impulse control as a measure 
of disinhibition with the use of PANSS item G14 and 
the degree of fluctuation of psychiatric symptoms with 
Symptomatic Organic Mental Disorder Assessment 
Scale (SOMAS) item A [14]. In addition, the nursing 
staff evaluated the degree of irritability and disorienta-
tion with the Brøset Violence checklist (BVC) [15]. Sleep 
variables were recorded by an actigraph worn around 
the wrist for 24 h soon after admission (Actiwatch Spec-
trum, Philips Respironics Inc., Murrysville PA, USA) 
[16], mean time until the actigraphy recording started 
was 2.2 (SD 2.2) days after admission. A blinded assessor 
Fig. 1 Flow chart over patient recruitment, cases, and controls. 
aThree patients were positive for both NMDAR and GAD65 antibodies. 
bImmunglobulin (Ig) isotype 11/3/9 (IgA/IgG/IgM), titer, median 
(range) 1:32 (1:10–1:1000), 2 patients were positive to both NMDAR 
IgM and IgA antibodies. cIg isotype 2/6/6 (IgA/IgG/IgM) titer, median 
(range) 1:10 (1:10–1:100). d Ig isotype 1/8/0 (IgA/IgG/IgM), titer, 
median (range) 1:10 (1:10–1:320). See Additional file 1 for full list of 
antibody isotype and endpoint titer. CASPR2 contactin‑associated 
protein 2, GAD65 glutamic acid decarboxylase 65, Ig immunoglobulin, 
NMDAR N‑methyl‑d‑aspartate receptor
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scored the actigraphy recordings. For each patient a rest 
interval at nighttime was set by visual inspection. The 
actigraphy software (Actiware, version 5.70.1) then auto-
matically calculated the variables “total sleep time” and 
“wake after sleep onset” during the rest interval using 
the Immobile Minutes algorithm of 10 min, and a wake 
threshold after sleep onset of 40 activity counts (medium 
sensitivity), which has been used in validation studies 
[17, 18]. All other clinical characteristics were extracted 
from patient charts by blinded examiners who reviewed 
charts from the 24  h following admission. Psychiatric 
diagnoses were set according to the International Clas-
sification of Diseases (ICD)-10 criteria for research [19] 
in a consensus meeting including the physician or psy-
chologist in charge of the treatment of the patient and at 
least two psychiatrists and/or senior clinical psycholo-
gist. The main diagnosis was registered in this study. 
Patients were asked for life-time history of seizures and 
evaluated with regards to whether or not alcohol or ille-
gal substances had been consumed during the days/
weeks prior to admission. This evaluation consisted of 
patient interviews, alcohol breathing tests and urine 
analyses of alcohol, benzodiazepines (oxazepam, desme-
thyldiazepam, nitrazepam, flunitrazepam, clonazepam, 
and alprazolam), zopiclone, stimulants (amphetamine, 
metamphetamine, 3,4-methylendioksymetamphetamine, 
3,4-methyl-dioxy-amphetamine, ephedrine, and benzo-
ylecgonine), opioids (morphine, codeine, etylmorphine, 
methadone, buprenorphine, pholcodine, and oxycodone) 
carisoprodol, meprobamate, cannabis, and phencyclidine 
(Liquid chromatography with mass spectroscopy).
Serological analysis
Sera were tested for the presence of anti-neuronal anti-
bodies directed against NMDAR, LGI1, CASPR2, 
AMPAR,  GABABR and GAD65 (IgA, IgG and IgM) 
using transfected HEK293 cells expressing the respec-
tive recombinant target antigens (Euroimmun, Lübeck, 
Germany) [20, 21]. Samples were classified as positive 
or negative based on fluorescence intensity of the trans-
fected cells in direct comparison with non-transfected 
cells and control samples. Endpoint titers were defined as 
the last dilution showing a measurable degree of fluores-
cence, with 1:10 being the cut-off for positivity [20, 21].
Ethics
On the day after admission a psychiatrist or senior clini-
cal psychologist evaluated each patient’s ability to con-
sent. Patients without ability to consent were excluded. 
Included patients gave written, informed consent. The 
study was conducted in accordance with the Declara-
tion of Helsinki and approved by The Regional Com-
mittee for Medical Research Ethics, Central Norway 
(2011/137). The data for the present study were collected 
as part of a previous clinical trial, “Agitation in the Acute 
Psychiatric Department”, which was prospectively regis-
tered on https ://clini caltr ials.gov/ on August 11th 2011 
(NCT01415323).
Statistics
We compared patients with a positive serology for 
NMDAR, CASPR2 or GAD65 antibodies with their 
respective age- and sex-matched controls for the pres-
ence and degree of psychiatric symptoms as outlined in 
Tables 1 and 3. Categorical variables were analyzed using 
the Chi square test or Fisher’s exact test. Continuous 
Table 1 Patients with and without anti-neuronal antibodies were compared on the following clinical characteristics
aud auditive, CASPR2 contactin-associated protein 2, GAD65 glutamic acid decarboxylase 65, n/a not applicable (because the systematic literature search did not 
reveal associations between the symptom variable and the specific antibody), NMDAR N-methyl-d-aspartate receptor, olf olfactory, PANSS positive and negative 
syndrome scale, PANSS-EC positive and negative syndrome scale- excited component, SOMAS Symptomatic Organic Mental Disorder Assessment Scale, tact tactile, Vis 
visual
Clinical characteristic NMDAR CASPR2 GAD65 Variable Obtained Definitions
Hallucinations X X n/a Dichotome (Yes/No) Retrospective Vis., aud., tact. and/or olf.
Delusions X X n/a Dichotome (Yes/No) Retrospective Described in chart
Lowered mood X X X Dichotome (Yes/No) Retrospective Described in chart
Elevated mood X n/a n/a Dichotome (Yes/No) Retrospective Described in chart
Irritability X n/a X Dichotome (Yes/No) Prospective Brøset Violence Checklist
Disorientation X X X Dichotome (Yes/No) Prospective Brøset Violence Checklist
Disinhibition X n/a n/a Continuous (1–7) Prospective PANSS Item G14
Agitation X X X Continuous (5–35) Prospective PANSS‑EC
Symptom fluctuation X n/a n/a Continuous (1–10) Prospective SOMAS Item A
Total sleep time (actigraphy) X X n/a Continuous (min) Prospective According to actigraphy software algorithms
Wake after sleep onset (actigraphy) X X n/a Continuous (min) Prospective According to actigraphy software algorithms
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variables were compared using the T test or Mann–
Whitney U-test. Alpha level was set at 0.05. Adjustment 
for multiple comparisons was not performed due to the 
exploratory study design. Statistical analyses were done 
in SPSS 21 (SPSS, Chicago, US-IL).
Results
Demographic and clinical data
The inclusion rate was 52% (340 out of 654 admitted 
patients). There were no significant differences in age 
(p = 0.64, Mann–Whitney U test) or sex (p = 0.67, chi- 
square test) between included and non-included patients. 
However, there was a difference in diagnostic distribution 
between the groups (p < 0.001, Chi square test). This was 
attributable to overrepresentation of patients suffering 
from depressive and bipolar disorders, and underrepre-
sentation of patients suffering from psychotic disorders 
and patients not fulfilling ICD-10 criteria for a specific 
psychiatric disorder (Z-diagnosis) among the included 
patients (data not shown).
Demographic and clinical data of cases and controls 
are presented in Table 2. Compared to controls, NMDAR 
antibody positive patients had a higher prevalence of 
alcohol and substance use prior to admission (76 vs. 50%, 
p = 0.047) and received antidepressant drugs more often 
at discharge (43 vs. 17%, p = 0.024). GAD65 antibody 
Table 2 Demographic and clinical data of patients with NMDAR, CASPR2 or GAD65 antibodies and of their controls
CASPR2 contactin-associated protein 2, eq equivalents, GAD65 glutamic acid decarboxylase 65, med medication, NMDAR N-methyl-d-aspartate receptor, SD standard 
deviation
*p < 0.05
a 3 patients with organic mental disorder (F00–09), 13 patients with anxiety disorders (F40–49), 7 patients with personality disorders (F60–69), 1 patient with mental 
retardation (F70–79), 1 patient with ADHD (F90–98) and 5 patients without specific psychiatric disorder (Z00–99); bchlorpromazine equivalents; cself-reported at 
admission (missing data; NMDAR, 3 cases and 6 controls; CASPR2, 4 cases and 5 controls; GAD, 1 control
NMDAR CASPR2 GAD65
Cases (n = 21) Controls (n = 42) Cases (n = 14) Controls (n = 28) Cases (n = 9) Controls (n = 18)
Age, mean (SD) 48.6 (16.3) 46.7 (14.2) 45.0 (16.1) 43.4 (14.7) 47.1 (14.0) 45.8 (11.8)
Sex, men (%) 62 62 71 71 56 56
Education, n (%)
 ≤ 9 years 9 (43) 20 (48) 6 (43) 9 (32) 4 (44) 7 (39)
 10–12 years 7 (33) 14 (33) 2 (14) 13 (46) 4 (44) 9 (50)
 > 12 years 5 (24) 8 (19) 6 (43) 6 (21) 1 (11) 2 (11)
Psychiatric diagnosis, n (%)
 Substance use disorder (F10–19) 4 (19) 7 (17) 3 (21) 6 (21) 2 (22) 3 (17)
 Psychotic disorder (F20–29) 1 (6) 6 (14) 2 (14) 6 (21) 1 (11) 1 (6)
 Affective disorder (F30–39) 8 (38) 20 (48) 5 (36) 12 (43) 3 (33) 9 (50)
 Other psychiatric  disordersa 8 (38) 9 (21) 4 (29) 4 (14) 3 (33) 5 (28)
Psychopharmacological med. at admis‑
sion, n (%)
 Antipsychotic med. 6 (29) 13 (31) 5 (36) 10 (36) 3 (33) 5 (28)
 Antipsychotic dose, mean (SD)b 482 (422) 458 (302) 241 (185) 324 (170) 1071 (124) 469 (276)*
 Antidepressive med. 8 (38) 9 (21) 4 (29) 8 (29) 3 (33) 6 (33)
 Mood stabilizing med. 3 (14) 10 (24) 2 (14) 4 (14) 2 (22) 3 (17)
 No psychopharmacological med. 10 (48) 18 (43) 5 (36) 12 (43) 4 (44) 8 (44)
Psychopharmacological med. at dis‑
charge, n (%)
 Antipsychotic med. 9 (43) 26 (62) 6 (43) 18 (64) 5 (56) 11 (61)
 Antipsychotic dose, mean (SD)b 418 (449) 408 (331) 222 (203) 342 (226) 784 (403) 331 (254)*
 Antidepressive med. 9 (43) 7 (17)* 4 (29) 7 (25) 2 (22) 6 (33)
 Mood stabilizing med. 6 (29) 15 (36) 5 (36) 6 (21) 2 (22) 5 (28)
 No psychopharmacological med. 5 (24) 10 (24) 3 (21) 5 (18) 2 (22) 5 (28)
Number of days admitted, mean (SD) 9.5 (11.4) 9.9 (9.1) 9.5 (6.1) 10.1 (11.6) 9.6 (9.3) 9.1 (8.3)
Alcohol or substance use days/weeks 
prior to admission, n (%)
16 (76) 21 (50)* 10 (71) 18 (64) 7 (78) 10 (56)
History of  seizuresc 1 (6) 9 (25) 4 (40) 3 (13) 2 (22) 3 (18)
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positive patients received higher doses of antipsychotic 
medication compared to controls both at admission and 
discharge [Chlorpromazine equivalents mean (SD) 1071 
(124) vs. 469 (276), p = 0.013, and 784 (403) versus 331 
(254), p-value = 0.015, respectively]. None of the anti-
GAD65 positive cases or controls had diabetes mellitus 
type I.
Clinical characteristics
None of the clinical parameters differed between patients 
with NMDAR, CASPR2 and GAD65 antibodies and their 
respective controls (Table 3). None of the NMDAR IgG 
positive patients had symptoms or signs of NMDAR 
encephalitis.
Discussion
In this large cohort of patients admitted to acute psychi-
atric inpatient care, patients who were serum positive or 
negative to anti-neuronal antibodies had a similar psy-
chiatric phenotype. Specifically, patients with NMDAR, 
CASPR2 and GAD65 antibodies did not exhibit psychi-
atric symptoms suggestive of autoimmune encephalitis 
more frequently than controls.
Previous studies in patients with psychiatric disorders 
have explored the prevalence of anti-neuronal antibod-
ies in different diagnostic groups. It is still controversial 
whether or not the prevalence of anti-neuronal antibod-
ies is increased in patients with first episode or chronic 
psychosis [2, 8–10, 22, 23]. A limited number of studies 
have addressed clinical characteristics in anti-neuronal 
antibody-positive and -negative psychiatric patients 
irrespective of diagnostic categories. Hammer et al. [24] 
did not find any differences in PANSS or Global Assess-
ment of Function (GAF) when comparing patients 
with schizophrenia who were positive or negative for 
NMDAR antibodies. Similarly, in a cohort of patients 
with first-episode psychosis PANSS scores, cognitive 
testing and catatonia symptoms were not clinically sig-
nificant different in anti-neuronal antibody positive 
(NMDAR, CASPR2, LGI1 or  GABAA receptor antibod-
ies) and negative patients [9]. The authors of a study 
including patients with both first episode and chronic 
schizophrenia found more severe psychotic symptoms 
(PANSS scores) in NMDAR antibody positive com-
pared to negative patients [10]. The studies in this field 
are heterogeneous and the results depend to a certain 
degree on the antibody detection method used. Fixed 
and live cell-based assays are the most commonly used 
methods for anti-neuronal antibody detection. Using a 
novel single molecule-based imaging approach, Jezequel 
et al. [10] recently showed that NMDAR antibodies from 
schizophrenia patients alter the surface dynamics of the 
NMDAR in contrast to NMDAR antibodies from healthy 
controls. Jezequel et  al. [25] found that fixed cell-based 
assays (such as the one used in this study) have a lower 
sensitivity for detection of IgG antibodies in psychotic 
patients compared to live cell-based assays. Hence, it is 
possible that the use of other antibody detection methods 
in the present study would have yielded slightly differ-
ent results. Another possible explanation for the lack of 
phenotypic differences is the low antibody titers found in 
our patients; alternatively, the lack of significant findings 
in our study could reflect a lack of clinical significance of 
these antibodies for acute psychiatric patients in general. 
Table 3 Psychiatric symptoms in antibody positive cases (+) and controls (−)
CASPR2 contactin-associated protein 2, GAD65 glutamic acid decarboxylase 65, NMDAR N-methyl-d-aspartate receptor, SD standard deviation
a Fisher’s exact test if not stated otherwise. Data missing on bNMDAR (3 cases, 1 control), CASPR2 (1 case, 3 controls), GAD65 (1 control); cNMDAR (3 cases, 1 control); 
dNMDAR (1 case), CASPR2 (1 case, 1 control), GAD65 (1 case); eNMDAR (1 case), CASPR2 (1 case, 2 controls), GAD65 (1 case); fCASPR2 (1 case, 1 control); gNMDAR (3 
cases, 7 controls); hNMDAR (10 cases, 16 controls), CASPR2 (6 cases, 14 controls); iChi square; jMann Whitney U test; kT-test
Clinical characteristic NMDAR pa CASPR2 pa GAD65
+ n = 21 − n = 42 + n = 14 − n = 28 + n = 9 − n = 18 pa
Hallucinations, n (%) 3 (14.3) 1 (2.4) 0.10 0 (0) 3 (10.7) 0.54
Delusions, n (%) 2 (9.5) 7 (16.7) 0.71 2 (14.3) 3 (10.7) 1.00
Lowered  moodb, n (%) 10 (55.6) 16 (39.0) 0.24i 8 (61.5) 15 (60.0) 0.93i 5 (55.6) 11 (64.7) 0.69
Elevated  moodc, n (%) 2 (11.1) 7 (17.1) 0.71
Irritabilityd, n (%) 3 (15.0) 6 (14.3) 1.00 3 (23.1) 5 (18.5) 1.00 1 (12.5) 5 (27.8) 0.63
Disorientatione, n (%) 1 (5.0) 7 (16.7) 0.26 4 (30.8) 4 (15.4) 0.40 0 (0) 2 (11.1) 1.00
Disinhibition (median (range)) 1 (1–6) 1 (1–6) 0.57j
Agitation (median (range))f 8 (5–31) 8 (5–32) 0.62j 7 (5–27) 10 (5–21) 0.34j 10 (5–17) 8 (5–23) 0.98j
Symptom fluctuation (median (range))g 2 (1–7) 3 (1–8) 0.89j
Total sleep time (min) (mean (SD))h 458 (115) 476 (112) 0.66k 438 (109) 442 (114) 0.93k
Time awake after sleep onset (min) (mean (SD))h 39 (23) 37 (35) 0.90k 47 (18) 40 (24) 0.51k
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Hence, whether or not phenotypical differences are pre-
sent in psychiatric patients with higher antibody titers is 
an important question for further research. To further 
investigate this, future studies should include cerebrospi-
nal fluid (CSF) analyses, electroencephalography (EEG) 
and brain imaging.
NMDAR antibody positive patients were treated more 
often with antidepressants than controls. These findings 
could be coincidental. However, it is also possible that 
excessive use of antidepressants indicates a higher bur-
den of depressive and/or anxious symptoms in NMDAR 
positive patients, although we were unable to detect such 
differences in our retrospective chart assessment. The 
increased frequency of alcohol and substance use prior 
to admission in NMDAR antibody positive patients may 
suggest self-medication for depressive and/or anxious 
symptoms. However, an influence of alcohol and sub-
stance use on NMDAR antibody titers cannot be ruled 
out. The NMDAR is implicated in addiction in several 
ways. For instance, associations have been found between 
addiction and genes coding for NMDAR subunits [26]; 
alcohol has acute and chronic effects on NMDAR func-
tioning [27]; and NMDAR modulators are used to treat 
alcohol dependency [28]. Interestingly, alcohol and illicit 
substances can cause blood brain barrier dysfunction [29, 
30], which might facilitate the occurrence of NMDAR 
antibodies by exposing NMDAR to lymphoid cells. 
However, the exact reasons for the observed association 
between NMDAR antibodies and alcohol and substance 
remains unknown. GAD65 antibody positive patients 
used higher doses of antipsychotic drugs compared to 
antibody negative patients, which could imply a more 
severe symptomatology in these patients. Alternatively, 
antipsychotic medication might also lead to enhanced 
production of GAD65 antibodies. A similar association 
is known for chlorpromazine and antinuclear antibodies 
[31, 32].
The present study has limitations. The inclusion rate 
of 52% is similar to other studies in this setting [33, 34]. 
However, there is a risk of selection bias (i.e. patients with 
a higher severity of symptoms may decline participation 
or lack ability to consent more often than patients with 
less severe phenotypes). Patients with affective disorders 
were overrepresented and psychotic disorders under-
represented in our study. We included patients with all 
isotypes of NMDAR, CASPR2 and GAD65 antibodies 
(IgG, IgA and IgM). Whereas most known relevant anti-
neuronal antibodies are of the IgG isotype, the results of 
pathogenicity studies of NMDAR IgA and IgM antibodies 
show their pathogenic potential in vitro [5, 24, 35, 36] and 
in a study of patients with stroke [37], although authors 
from another study concluded that NMDAR IgA and IgM 
antibodies do not alter NMDAR levels [38]. It is possible 
that our study would have yielded a different result if we 
had focused exclusively on IgG positive patients. Also, 
small group sizes and the categorical nature of several 
of the variables may have resulted in a lower sensitivity 
for detecting clinical differences. Although age- and sex-
matched control subjects were randomly selected, some 
differences in diagnostic distribution and psychopharma-
cological treatment between the case and control group 
were present (Table 3).
Conclusion
Based on our findings, patients admitted to acute psy-
chiatric care with and without NMDAR, CASPR2 and 
GAD65 antibodies have a similar clinical phenotype. 
However, of note, absence of phenotypic differences 
between patients with and without anti-neuronal anti-
bodies is not evidence that these antibodies lack clini-
cal significance. Even if anti-neuronal antibodies played 
a role in only a minor subset of psychiatric patients, 
this would have important clinical implications as these 
patients might benefit from immunomodulatory treat-
ment. This area must be further investigated by large 
prospective longitudinal multicenter studies that include 
cerebrospinal fluid analyses, brain imaging and electro-
physiological investigations.
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